Lung cancer attention month: 8 cancer problems worthy of attention

Xinnuo Medicine 2018-09-28

According to statistics released by Nature, the annual incidence of lung cancer in 2012 (per 100,000 people). In the United States, the number of people dying from lung cancer each year is higher than the combined deaths from colon, breast, and prostate cancer. Lung cancer is the leading cause of cancer-related deaths, both male and female. According to the American Cancer Society, more than 200,000 lung cancers are diagnosed each year, and more than 150,000 patients will die from the disease, which is estimated to account for 28% of all cancer deaths this year.

November is the International Year of Lung Cancer Concern. This article lists eight notable problems related to lung cancer and hopes to be helpful to clinicians.

1. ASCO: EGFR, ALK testing should be provided for all patients with lung adenocarcinoma

ASCO has signed a joint clinical practice guideline between the American Society of Pathologists (CAP)/International Lung Cancer Research Association (IASLC)/Molecular Pathology Association (AMP), which addresses the appropriate use of EGFR mutations and ALK in patients with lung cancer. Rearrange the problem of checking.

An important recommendation of the guidelines is that clinicians should provide EGFR and ALK tests for all lung adenocarcinomas and mixed lung cancer patients with adenocarcinoma.

2. Prolonged first-line treatment of non-small cell lung cancer does not bring survival benefits

According to a systematic review and meta-analysis, patients with advanced non-small cell lung cancer who used 6 cycles of platinum-based therapy did not show a survival advantage compared with patients who underwent 3 or 4 cycles of treatment.

3. Lung cancer targeted therapy drives the field forward

According to Dr. Mark G. Kris, who commemorates the Sloan Kettering Cancer Center, recent advances in genomics in the treatment of lung cancer may drive the advancement of cancer treatment.

Dr. Mark G. Kris said at the US News and World Report tomorrow hospital forum that “the treatment is no longer a one-size-fits-all treatment.” “The difference is that we now have more biological knowledge and testing. The ability of these concepts, and we also have the means of targeted therapy."

4. Non-small cell lung cancer: two new mutations associated with resistance to ALK inhibitors

The study found that two new ALK mutations, V1180L and I1171T, are associated with resistance to crizotinib and alectinib, but are sensitive to other new generation non-small cell lung cancer ALK tyrosine kinase inhibitors.

5. Lung cancer clinical trials usually exclude cancer survivors

The study found that many patients are often excluded from lung cancer trials because of their previous history of cancer. In addition, this standard appears to be used in trials with multiple characteristics, with more than two-thirds of the trials ending at non-survival endpoints.

6. Electronic cigarettes do not help cancer patients to quit smoking

A study of cancer patients who smoked showed that patients who use e-cigarettes are more dependent on nicotine than the ones who do not use e-cigarettes, and are equally or less likely to quit traditional cigarettes.

7. Doctors involved in multidisciplinary discussions are more likely to participate in clinical trials

According to the results of the study presented at the ASCO Quality Care Forum, doctors who treat lung cancer or colorectal cancer every week at the Multidisciplinary Symposium on Cancer are more likely to participate in clinical trials.

8. CMS supports medical insurance coverage for lung cancer screening; low-dose CT, is it suitable for China?

CMS has signed a draft that supports health insurance coverage for lung cancer screening for low-dose CT performed annually for individuals who meet specific criteria.

The United States has implemented low-dose CT for lung cancer screening, so is it equally applicable to China? Prof. Fang Jian from the University Cancer Hospital published an article “Low-dose CT, is it applicable in China?”, and listed relevant research evidence to discuss this issue. “Early testing can reduce the risk of lung cancer death, but how The transformation into policy and clinical practice changes depends on further research and analysis."

Hot News

Contact Us

Jinan Xinnuo Pharmaceutical Technology Co., Ltd.

Service hotline: +86- 18615688656 18653156686

E_mail:sales@xinnuopharma.com sabrina@xinnuopharma.com

Send Email

Copyright: Jinan Xinnuo Pharmaceutical Technology Co., Ltd. All rights reserved.   Powered by:MRWL